PATIENT OUTCOMES 6 AND 12 MONTHS AFTER ALTA, EDEN AND OMEGA ARDS NETWORK TRIAL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 ALI的发病率高于以前认识到的，由于ICU死亡率的提高和ALI风险人群的老龄化，存活者的数量正在增加。然而，这些幸存者忍受许多长期的病态。到目前为止，绝大多数ALI临床试验都没有考虑这些长期结局，而是只关注基于短期死亡率的终点。为了推进这一领域的发展，需要进行更大规模的纵向研究，以全面了解幸存者的长期身体、认知和心理健康状况，并测试特定的ICU治疗如何影响这些结果。我们的提案做出了以下重要贡献：对肌力、人体测量学和认知进行了深入的临床评价，这些在先前的研究中没有得到完全评价，但在幸存者中可能普遍和严重受损，并可能通过母试验中测试的ICU治疗得到改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The incidence of ALI is higher than previously recognized and the number of survivors is growing due to improving ICU mortality and an aging population at risk for ALI. However, these survivors endure many long-term morbidities. To date, the vast majority of clinical trials in ALI have not considered these long-term outcomes, instead focusing exclusively on short-term mortality-based end points. To advance this field, larger-sized longitudinal studies are needed to comprehensively understand the long-term physical, cognitive and mental health status of survivors and to test how specific ICU therapies may affect these outcomes. Our proposal makes the following important contribution: in-depth clinical evaluation of muscle strength, anthropometrics and cognition which have been incompletely evaluated in prior studies but are likely commonly and severely impaired in survivors, and potentially improved by the ICU therapies tested in the parent trials.